SARS-CoV-2 & Flu A/B
RNA STAR Complete

Test Benefits

The LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete multiplex assay is intended for the rapid qualitative detection and differentiation of nucleic acid from the SARS-CoV-2, Influenza A, and/or Influenza B viruses in nasopharyngeal swabs from individuals suspected of COVID-19 and/or influenza by their healthcare provider

  • Reliable and robust performance when compared to traditional RT-PCR tests.
  • Direct amplification within 20 minutes drives lab’s efficiency and productivity.

Test Workflows

SARS-CoV-2 & Flu A/B RNA STAR Complete - Test Workflows

Test Performance

SARS-CoV-2 & Flu A/B RNA STAR Complete - Test Performance

SARS-CoV-2 RNA STAR, SARS-CoV-2 RNA STAR Complete, SARS-CoV-2 & Flu A/B RNA STAR Complete have not been FDA cleared or approved but have been authorized by FDA for emergency use under an EUA for use by authorized laboratories. SARS-CoV-2 RNA STAR and SARS-CoV-2 RNA STAR Complete have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. SARS-CoV-2 & Flu A/B has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, and influenza B, not for any other viruses or pathogens. The emergency use of SARS-CoV-2 RNA STAR, SARS-CoV-2 RNA STAR Complete, SARS-CoV-2 & Flu A/B RNA STAR Complete is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated, or authorization is revoked sooner.

Users should refer to the LumiraDx SARS-CoV-2 RNA STAR, SARS-CoV-2 RNA STAR Complete, SARS-CoV-2 & Flu A/B RNA STAR Complete Instructions for Use posted on the FDA website for all IVD products used under Emergency Use Authorization.

In Vitro Diagnostics EUAs - Molecular Diagnostic Tests for SARS-CoV-2 | FDA

BetterHealthExperiencesOutcomes

Supporting healthier lives, for individuals, communities and wider society

Enabling responsive, personal relationships between patients and care teams.

Controlling and reducing costs to help ease pressure on healthcare budgets.

Be Informed

SIGN UP FOR NEWS